Surgical and endovascular repair for type B aortic dissections with mesenteric malperfusion syndrome: A systematic review of in-hospital mortality

Vishnu M. Chandra, MD, a Elizabeth L. Norton, MD, b Minhaj S. Khaja, MD, a,c Daniel Giraldo Herrera, MD, a David M. Williams, MD, c and Bo Yang, MD, PhD d

ABSTRACT

Objectives: Mesenteric malperfusion is a feared complication of aortic dissection, with high mortality. The purpose of this study was to systematically review in-hospital mortality (IHM) of endovascular and surgical management of acute and chronic Stanford type B aortic dissections (TBAD) complicated by mesenteric malperfusion (MesMP).

Methods: A systematic search of English language articles was conducted in relevant databases. Data on patient demographics, procedure details, and survival outcomes were collected. Reports were classified by type of intervention performed. Studies that failed to report patient-level outcomes based on specific intervention performed or IHM were excluded. Retrospective chart review of previously published data from a single institution was also performed to further identify cases of TBAD that were managed endovascularly. The Fisher exact test was performed to determine statistical significance.

Results: In total, 37 articles were suitable for inclusion in this systematic review, which yielded 149 patients with a median age 55.0 years (interquartile range, 46.5-65 years) and 79% being male. Overall, in-hospital mortality was 12.8% (19/149) and was similar between endovascular and open surgical interventions (13% vs 11%, \(P = .99\)). Among endovascular strategies, IHM was greater, although not statistically significant in the thoracic endovascular aortic repair group compared with the fenestration/stenting without thoracic endovascular aortic repair group (24% vs 11%, \(P = .15\)).

Conclusions: Multiple strategies exist for the management of TBAD with MesMP; however, a majority of cases were managed endovascularly. Despite advances in therapies, mortality remains high at 13%. (JTCVS Open 2022;12:37-50)

From the Division of Vascular and Interventional Radiology, Department of Radiology & Medical Imaging, University of Virginia Health, Charlottesville, Va; Division of Cardiothoracic Surgery, Department of Surgery, Emory University, Atlanta, Ga; and Division of Vascular and Interventional Radiology, Department of Radiology, and Division of Cardiac Surgery, University of Michigan, Ann Arbor, Mich.

Dr Chandra and Norton contributed equally to this article and are first authors. Drs Williams and Yang contributed equally to this article and are senior authors. Received for publication Oct 8, 2021; revisions received July 6, 2022; accepted for publication July 20, 2022; available ahead of print Aug 30, 2022. Address for reprints: Minhaj S. Khaja, MD, University of Virginia Health, 1215 Lee St, Charlottesville, VA 22902 (E-mail: vmc2bw@hscmail.mcc.virginia.edu).

Copyright © 2022 The Author(s). Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.jtcs.2022.07.012

Type B aortic dissection (TBAD) is a life-threatening condition in which a tear develops in the intima of the aortic wall distal to the origin of the left subclavian artery. TBADs are often stratified into uncomplicated versus complicated to determine management strategy. The standard of care for uncomplicated TBAD is medical management with blood pressure and heart rate control to prevent aortic rupture and propagation of the dissection. Complicated TBAD denotes dissection accompanied by aortic rupture, refractory pain, rapid aortic expansion, uncontrollable hypertension, or malperfusion. 1 Malperfusion refers to inadequate blood...
flow to a vascular territory and is present in approximately 20% to 30% of type B aortic dissections.\(^1\)\(^2\) Malperfusion syndrome is decreased flow to vascular territory resulting in tissue/end-organ necrosis and dysfunction secondary to dissection-related impairment of blood flow. In particular, mesenteric malperfusion (MesMP) has been associated with a particularly poor prognosis and a significant increase in mortality (3- to 4-fold increase).\(^3\)

Diagnosis of MesMP is based on clinical, radiographic, and laboratory features, including the presence of abdominal pain (most common symptom), bloody diarrhea, tenderness to palpation, diminished blood flow in the superior mesenteric artery (SMA) with or without SMA thrombosis on computed tomography (CT) imaging, and signs of ischemia, such as thickened bowel wall, elevated lactate, and metabolic acidosis.\(^4\) The signs and symptoms of MesMP can be persistent or intermittent, contributing to the diagnostic challenge, but the symptoms often correlate to the degree of obstruction.\(^5\) Obstruction can be dynamic, static, or a combination of dynamic and static.\(^5\) Dynamic obstruction results from prolapse of the dissection flap across or into the ostium of the branch vessel, thereby obstructing flow with a degree of obstruction varying with blood pressure. Paradoxically, in many cases visceral organ perfusion improves with reduction in systemic blood pressure.\(^6\)\(^7\) Dynamic obstruction can usually be resolved with restoration of the true lumen in continuity with the heart. In contrast, static obstruction results from extension of the dissection into the branch vessel with inadequate or absent reentry based on manometry. Static obstruction must be relieved by an intervention targeting the particular mechanism of true lumen compromise including stenting, thrombolysis, thromboembolectomy, and fenestration.

The presence of MesMP in type B aortic dissection classifies it as a complicated TBAD, therefore necessitating intervention following initial medical stabilization. With the advent of endovascular therapies over recent years, multiple options exist for treating complicated type B aortic dissection, including thoracic endovascular aortic repair (TEVAR), fenestration and stenting, and open surgical repair.\(^2\)\(^6\)\(^8\) Endovascular therapy, specifically TEVAR, has been established as superior to open surgical repair for complicated TBAD in multiple studies and reviews.\(^9\)\(^-\)\(^12\) However, the primary goal of TEVAR is to cover the primary intimal tear to restore true lumen flow, which can resolve dynamic obstruction but does not reliably relieve static obstruction, which may require further intervention such as branch vessel stenting, thrombolysis, or thromboembolectomy. Endovascular fenestration with or without stenting with ancillary procedures such as thrombolysis can resolve both dynamic and static obstructions\(^8\) in one setting. Therefore, multiple options are available for the treatment of complicated TBAD; however, the optimal strategy remains uncertain and will depend on the mechanism of obstruction. Herein we report a systematic review to evaluate the different treatment strategies for TBAD complicated by MesMP syndrome.

**METHODS**

A systematic review was conducted of published literature on surgical or endovascular interventions performed for TBAD complicated by MesMP. This study was deemed exempt from formal institutional review by the institutional review board because identifiable human subjects were not studied. A systematic review of published literature on TBAD-MesMP was performed in adherence to the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines.\(^13\) Microsoft Excel (Microsoft) was used during article selection and data extraction. The present study encompasses peer-reviewed articles written in English.

**Literature Search Strategy**

The PubMed database (including articles indexed in Medline), Web of Science, and Ovid were searched from 1980 until 2020. The search was performed using varying combinations of the following key words: “TBAD,” or “CTBAD,” or “complicated type B,” or “aortic dissection,” and “visceral malperfusion,” or “visceral ischemia,” or “mesenteric malperfusion,” or “mesenteric ischemia,” or “renal malperfusion,” or “renal ischemia,” or “bowel malperfusion,” or “bowel ischemia.”

**Eligibility Criteria**

Upon completion of the literature search, article selection was executed in a 2-step approach involving abstract review, followed by full-text review. First, any publications gathered during the primary literature search were grouped by title, and duplicates were removed. Subsequently, each abstract was assessed for relevance by 2 of the authors, and any interauthor disagreement concerning article relevance was discussed between the authors; if agreement could not be reached, the article was arbitrated by the senior corresponding author. Exclusion criteria during the abstract review phase are outlined in the Preferred Reporting Items for Systematic Review and Meta-Analysis flow diagram (Figure 1); studies were excluded for the following reasons: (1) study did not report type B aortic dissection; (2) study did not report patients who had visceral ischemia as a presenting sign; (3) study did not report an endovascular or surgical intervention; (4) study was unrelated, that is, involving ischemia of nonaortic etiology, interventions on non-native aorta, laboratory measurement studies, diagnostic techniques, or animal or in vitro studies; (5) study abstract was not written in English; (6) study was a conference abstract, letter to editor, commentary, review article, or meta-analysis article; or (7) study abstract was unavailable. In some instances, studies that did not explicitly state our inclusion criteria but were suggestive thereof were advanced to full-text review for further evaluation.

Any study of humans involving the performance of surgical or endovascular intervention with measured outcomes of effectiveness and efficacy

---

**Abbreviations and Acronyms**

| Abbreviation | Definition                                      |
|--------------|------------------------------------------------|
| CT           | = computed tomography                          |
| IRAD         | = International Registry of Acute Aortic Dissection |
| MesMP        | = mesenteric malperfusion                      |
| SMA          | = superior mesenteric artery                   |
| TBAD         | = type B aortic dissection                     |
| TEVAR        | = thoracic endovascular aortic repair          |
was moved into the second phase of article selection. Exclusion criteria for full-text review were as follows: (1) study failed to separate type B and type A or non-A non-B dissection data; (2) study failed to separate mesenteric ischemia from renal ischemia; (3) study full-text did not report patients who had mesenteric ischemia as a presenting sign; (4) study full-text did not report a surgical or endovascular intervention; (5) the study full-text was unrelated as described in abstract review criteria; (6) the study used national or international registry data; (7) the study full-text was not written in English; (8) the study failed to present patient-level data; (9) the study full-text was unavailable; and (10) the study failed to present in-hospital mortality. Potentially duplicated cohorts by the same authors were avoided by extensively reviewing study periods, patient selection methods, patient characteristics, and procedural/surgical technique. In these situations, the study with the largest patient cohort was chosen. When there was disagreement regarding article inclusion, a third author was consulted. No new studies were identified when the reference lists of these full-text studies were reviewed. Studies were carefully reviewed to ensure that there were no overlapping patient populations.

Analysis Techniques

Demographic and independent variables extracted include male to female ratio, age, type of aortic dissection treated (acute vs chronic), clinical presentation (ie, additional types of ischemic syndromes), and type of intervention. Retrospective chart review of previously published data from a single institution was performed to identify demographic variables that were not available in the published manuscript. Outcome (dependent) measures recorded include in-hospital mortality, need for additional surgeries, need for bowel resection, and length of stay.

Statistical analysis was performed using SPSS, version 25 (IBM Corp). The Fisher exact test was used for comparison of all categorical variables. The Mann–Whitney U test was used to compare distributions of age in the endovascular and surgical treatment groups. Since some of the articles in the analysis had more than 1 patient, a binary logistic regression was performed with article as random effect and type of intervention (endovascular vs surgical) as fixed binary variable to look for possible association of outcome among patients from the same article.

RESULTS

Studies Meeting Inclusion Criteria

In total, 385 articles were identified, of which 348 were excluded (Figure 1). No randomized controlled trials were found comparing the various surgical and endovascular treatment options for MesMP syndrome associated with type B aortic dissection. Review of the bibliographies of included articles yielded 54 additional studies. In total, 37 articles comprising 10 retrospective reviews and 27 case reports were included. A summary of these studies is provided in Table 1, and their respective outcomes in Table 2.

Demographics and Presentation

In total, 149 patients with MesMP (117 male/31 female; median age 55.0 years (interquartile range [IQR] 46.5-65 years)) were identified in the study. The cohort comprised 148 adults and 1 pediatric patient, an 11-year-old female (Leprince and colleagues). The etiology of type B aortic dissection was only reported in 73% of studies, with the most common reported cause being hypertension/idiopathic. Two patients had Marfan syndrome (Payabyab and colleagues, Wang and colleagues), and
| Study                          | Type of study | Total patients in study | Total patients with MesMP | Median age, y | Sex ratio (M:F) | Etiology | Chronicity | Clinical presentation | Additional malperfusion? |
|-------------------------------|---------------|-------------------------|---------------------------|---------------|----------------|----------|------------|-----------------------|------------------------|
| Shiya et al, 2007 [14]        | RCS           | 51                      | 1                         | 55            | 1:0            | N/P      | Acute      | N/P                   | R                      |
| Miyachi et al, 2014 [15]      | CR            | 1                       | 1                         | 48            | 1:0            | HTN      | Acute      | Back pain, elevated LFTs | No                     |
| Suzuki et al, 2015 [16]       | CR            | 1                       | 1                         | 50            | 1:0            | HTN      | Acute      | Acute back/chest pain, normal labs | No                     |
| Yamakado et al, 1998 [17]     | CR            | 1                       | 1                         | 58            | 1:0            | HTN      | Acute      | Severe abdominal pain  | No                     |
| Yoshiga et al, 2015 [18]      | CR            | 1                       | 1                         | 69            | 1:0            | HTN, hx of EVAR | Acute      | Worsening abdominal pain and melena | LE                     |
| Kazimierzczak et al, 2018 [19]| CR            | 1                       | 1                         | 11            | 0:1            | Idiopathic (no marfanoid features) | Acute      | Chest pain, peritonitis, sepsis | R                      |
| Leprince et al, 2004 [20]     | CR            | 1                       | 1                         | 63            | unk            | N/P      | Acute      | Abdominal pain         | No                     |
| Ito et al, 2003 [21]          | CR            | 1                       | 1                         | 72            | 1:0            | HTN      | Acute      | Paralytic ileus and occult blood in gastric drainage | R + LE                  |
| Bao et al, 2010 [22]          | CR            | 1                       | 1                         | 50            | 1:0            | N/P      | Acute      | Acute abdominal pain   | No                     |
| Chang et al, 2001 [23]        | CR            | 1                       | 1                         | 56            | 0:1            | N/P      | Acute      | Severe abdominal pain, ileus | R + LE                  |
| Payababan et al, 2017 [24]    | CR            | 1                       | 1                         | 29            | 0:1            | MFS, HTN | Acute on chronic | Acute abdominal pain | No                     |
| Petrelli et al, 2013 [25]     | CR            | 1                       | 1                         | 46            | 0:1            | N/P      | Acute      | Acute abdominal pain    | LE                     |
| Santo et al, 2007 [26]        | CR            | 1                       | 1                         | 56            | 0:1            | N/P      | Acute      | Elevated LFTs, back pain | R                      |
| Son et al, 2012 [27]          | CR            | 1                       | 1                         | 76            | 0:1            | N/P      | Acute      | Abdominal pain          | R                      |
| Iyer et al, 2009 [28]         | CR            | 1                       | 1                         | 77            | 1:0            | HTN, hx of EVAR | Acute      | Abdominal pain, elevated lactate, LFTs, amylase | R + LE                  |
| Verhoye et al, 2008 [29]      | RCS           | 16                      | 3                         | 40 (40-46)    | 1:2            | HTN      | Acute      | Variable               | LE (1), R + LE (1)     |
| Slonim et al, 1996 [30]       | RCS           | 9                       | 5                         | 47 (42-62)    | 3:2            | HTN      | Acute      | 3 Acute Chronic        | Variable (2)            |
| Sfyroeras et al, 2011 [31]    | RCS           | 23                      | 5                         | 63 (60-71)    | 4:1            | HTN      | Acute      | Variable               | R (1), R + LE + S (1)  |
| Lai et al, 2018 [32]          | CR            | 1                       | 1                         | 52            | 1:0            | HTN      | Acute      | Intermittent abdominal pain | R                      |
| Filipponi et al, 2013 [33]    | CR            | 1                       | 1                         | 67            | 1:0            | HTN      | Acute      | Persistent abdominal pain | No                     |
| Howell et al, 1997 [34]       | CR            | 1                       | 1                         | 40            | 1:0            | HTN      | Acute      | Abdominal pain, bloody stool, perforated colon on CT | R                      |
I patient reportedly was using cocaine before the dissection (Vedantham and colleagues\(^{48}\)). There were no reported cases of aortic dissection secondary to trauma. Three patients had a previous history of aortic surgery for aneurysmal disease (Yoshiga and colleagues,\(^{18}\) Iyer and colleagues,\(^{28}\) and Kim and colleagues\(^{42}\)). The aortic

| Study                      | Type of study | Total patients in study | Total patients with MesMP | Median age, y | Sex ratio (M:F) | Etiology | Chronicity | Clinical presentation | Additional malperfusion? |
|----------------------------|---------------|-------------------------|---------------------------|---------------|-----------------|----------|------------|----------------------|-------------------------|
| Kalangos et al, 2014\(^{48}\) | CR            | 1                       | 1                         | 47            | 0:1             | HTN      | Acute      | Persistent abdominal pain | R                       |
| Kuo et al, 2013\(^{36}\)  | CR            | 1                       | 1                         | 58            | 1:0             | HTN      | Acute      | Back and abdominal pain, elevated LFTs | R + LE                 |
| Kurumisawa et al, 2015\(^{17}\) | CR            | 1                       | 1                         | 56            | 1:0             | HTN      | Acute      | Acute abdominal pain, elevated LFTs and lactate  | R                      |
| Okada et al, 2005\(^{28}\) | CR            | 1                       | 1                         | 75            | 0:1             | N/P      | Acute      | Acute abdominal pain       | LE                     |
| Saitoh et al, 2012\(^{18}\) | CR            | 1                       | 1                         | 68            | 1:0             | N/P      | Acute      | Severe acute back and abdominal pain | No                     |
| Wang et al, 1999\(^{19}\)  | CR            | 1                       | 1                         | 32            | 0:1             | MFS, HTN | Acute      | Severe abdominal pain, vomiting, and bloody diarrhea | LE                     |
| Yamashiro et al, 2004\(^{48}\) | CR            | 1                       | 1                         | 63            | 1:0             | HTN      | Acute      | Severe abdominal pain      | No                     |
| Kim et al, 2014\(^{42}\)  | CR            | 1                       | 1                         | 78            | 1:0             | Ascending aorta replacement, HTN | Acute      | Severe back and abdominal pain | LE                     |
| Trimarchi et al, 2010\(^{43}\) | RCS           | 21                      | 4                         | 54 (52-56)    | 4:0             | HTN      | Acute      | Variable                        | R (2), LE (1)           |
| Williams et al, 1990\(^{44}\) | CR            | 1                       | 1                         | 46            | 1:0             | HTN      | Acute      | Severe back pain             | LE                     |
| Axtell et al, 2020\(^{45}\) | CR            | 3                       | 3                         | 58 (39, 76)   | 3:0             | N/P      | Acute      | N/P\(^{a}\)                    | No                     |
| Panneion et al, 2000\(^{46}\) | RCS           | 11                      | 2                         | 72 (68, 76)   | 1:1             | HTN      | Acute      | Variable                        | R (1), R + LE (1)       |
| Lauterbach et al, 2001\(^{47}\) | RCS           | 187                     | 8                         | 50 (45, 57)   | 8:0             | N/P      | Acute      | N/P\(^{a}\)                    | R (1), LE (1), R + LE (3) |
| Uchida et al, 2009\(^{48}\) | RCS           | 130                     | 15                        | 63 (53, 72)   | 9:6             | N/P      | Acute      | Variable                        | LE (4), R + LE (4)     |
| Vedantham et al, 2003\(^{49}\) | RCS           | 11                      | 4                         | 46 (41, 51)   | 4:0             | HTN (4), cocaine (1) | Acute      | Severe abdominal pain, GI bleeding (1), metabolic acidosis (3) | R (1), R + LE (3)       |
| Norton et al, 2020\(^{50}\) | RCS           | 182                     | 73                        | 53 (46, 61)   | 62:11           | N/P      | Acute      | Variable                        | R (17), LE (10), R + LE (36), S (1) |

\(\text{MesMP}\), Mesenteric malperfusion; \(M\), male; \(F\), female; \(\text{RCS}\), retrospective case series; \(\text{N/P}\), not provided; \(\text{CR}\), case report; \(\text{HTN}\), hypertension; \(\text{LFT}\), liver function test; \(\text{hx}\), history; \(\text{EVAR}\), endovascular aortic repair; \(\text{LE}\), lower extremity; \(\text{R}\), renal; \(\text{unk}\), unknown; \(\text{MFS}\), Marfan syndrome; \(\text{CT}\), computed tomography; \(\text{GI}\), gastrointestinal; \(\text{S}\), spinal.

\(^{a}\)For Shiya et al. 2007, and Axtell et al. 2020, the clinical presentation for mesenteric malperfusion was not provided.
| Study                          | Total patients with MesMP | Intervention | Clinical success (%) | IHM | Additional surgery/ procedure? | Need for bowel resection? | Major complications | LOS, d, median (first, third quartile) | Follow-up, mo |
|-------------------------------|---------------------------|--------------|----------------------|-----|-------------------------------|---------------------------|---------------------|--------------------------------------|--------------|
| Shiya et al, 2007\(^{14}\)    | 1                         | BS (SMA)     | 100                  | 0   | Diagnostic laparoscopy        | N                         | N                   | N/P                                  | N/P          |
| Miyachi et al, 2014\(^{15}\)  | 1                         | E-Fen + AS   | 100                  | 0   | N                             | N                         | N                   | 21                                  | 12           |
| Suzuki et al, 2015\(^{16}\)   | 1                         | BS (SMA)     | 100                  | 0   | Diagnostic laparoscopy; total arch replacement | N                         | Conversion to TAAD on POD7         | 90                                   | 24           |
| Yamakado et al, 1998\(^{17}\) | 1                         | BS (SMA)     | 100                  | 0   | N                             | N                         | N                   | 30                                  | 12           |
| Yoshiga et al, 2015\(^{18}\)  | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | N/P                                  | 6            |
| Kazimerczak et al, 2018\(^{19}\) | 1                  | TEVAR + BS (SMA) | 100          | 0  | N                             | N                         | N                   | Intraprocedural PEAs, but ROSC        | 21           | N/P         |
| Leprince et al, 2004\(^{20}\) | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | N/P                                  | 3            |
| Ito et al, 2003\(^{21}\)      | 1                         | AS           | 100                  | 0   | N                             | N                         | N                   | N/P                                  | 19           |
| Bao et al, 2010\(^{22}\)      | 1                         | TEVAR        | 100                  | 0   | Exploratory laparotomy        | Y                         | N                   | N/P                                  | N/P          |
| Chang et al, 2001\(^{23}\)    | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | N/P                                  | 2            |
| Payabyab et al, 2017\(^{24}\) | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | 4                                    | N/P          |
| Petrelli et al, 2013\(^{25}\) | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | N/P                                  | N/P          |
| Santo et al, 2007\(^{26}\)    | 1                         | TEVAR        | 0                    | 1   | N                             | N                         | TAAD and intrapericardial rupture with cardiac arrest, death on POD14 | 14           | N/P         |
| Son et al, 2012\(^{27}\)      | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | 16                                  | 12           |
| Iyer et al, 2009\(^{28}\)     | 1                         | TEVAR        | 100                  | 0   | N                             | N                         | N                   | 21                                  | 11           |
| Verhoye et al, 2008\(^{29}\)  | 3                         | TEVAR        | 66.7                 | 1   | Exploratory laparotomy (1)    | Y                         | Multiorgan failure (1)              | N/P                                  | N/P          |
| Slonim et al, 1996\(^{30}\)   | 5                         | 1 AS         | 100                  | 0   | Exploratory laparotomy (1)    | Y                         | Acute renal failure (1)             | N/P                                  | N/P          |
| Sfyroeras et al, 2011\(^{31}\) | 5                         | TEVAR        | 60                   | 2   | N                             | N                         | Respiratory failure (2)            | 8.5 (4.8, 12.5) | 12           |
| Lai et al, 2018\(^{32}\)      | 1                         | BS (CA)      | 100                  | 0   | N                             | N                         | N                   | N/P                                  | 1            |

(Continued)
TABLE 2. Continued

| Study | Total patients with MesMP | Intervention | Clinical success (%) | IHM | Additional surgery/procedure? | Need for bowel resection? | Major complications | LOS, d, median (first, third quartile) | Follow-up, mo |
|-------|---------------------------|--------------|----------------------|-----|-------------------------------|--------------------------|-------------------|---------------------------------------|--------------|
| Filippone et al, 2013 | 1 | OAR (Graft) + S-Fen | 100 | 0 | N * | N | N | N/P | 12 |
| Howell et al, 1997 | 1 | OAR (Graft) | 100 | 0 | N * | N | Y | N | N/P | 12 |
| Kalangos et al, 2014 | 1 | E Fen + BS (SMA) + DB (Ao-SMA) | 100 | 0 | N | N | N | 21 | 16 |
| Kuo et al, 2013 | 1 | IDB (Ax-Fem) | 100 | 0 | N | N | N | 21 | 14 |
| Kurumisawa et al, 2015 | 1 | OAR (S-Fen) | 100 | 0 | N * | N | N | 16 | N/P |
| Okada et al, 2005 | 1 | DB (LEIA-Ileocolic + LEIA-GEA) | 100 | 0 | N | N | N | N/P | 7 |
| Saitoh et al, 2012 | 1 | OAR (S-Fen) | 100 | 0 | N * | N | Y | N | N/P | N/P |
| Wang et al, 1999 | 1 | OAR (Graft) | 100 | 0 | N | N | N | N/P | N/P |
| Yamashiro et al, 2004 | 1 | DB (RCIA-SMA and GDA) | 100 | 0 | N * | N | N | N/P | 12 |
| Kim et al, 2014 | 1 | IDB (Fem-Fem then Ax-Fem bypass) | 100 | 0 | N | N | N | N/P | 12 |
| Trimarchi et al, 2010 | 4 | 4 OAR (S-Fen) | 75 | 1 | N | N | Multorgan failure (1) | N/P | 192 (138, 216) |
| Williams et al, 1990 | 1 | E Fen | 100 | 0 | N | N | Chronic mesenteric ischemia | 35 | NP |
| Axtell et al, 2020 | 3 | 1 hybrid; 2 hybrid + BS (SMA) | 100 | 0 | N | N | CVA (1) | 15.0 (12.5, 21.5) | N/P |
| Panneton et al, 2000 | 2 | 1 OAR (S-Fen + graft) 1 TEVAR + E-Fen | 50 | 1 (patient with OAR) | N | N | Acute renal failure (1) | N/P | N/P |
| Lauterbach et al, 2001 | 8 | 6 OAR (S-Fen) 1 E-Fen + BS (SMA) 1 OAR (Graft) | 87.5 | 1 (patient with E-fen + BS) | N * | Y (1) | Multi-organ failure (1), Permanent dialysis (1) | 17.5 (15, 28) | N/P |
| Uchida et al, 2009 | 15 | 1 TEVAR 2 BS (CA/SMA, SMA) 10 OAR (8 AS, 2 S-Fen) 2 DB (SMA) | 80 | 3 (1 TEVAR, 2 OAR) | N * | Y (1) | Multi-organ failure (2), Intra-operative aortic injury from sheath during TEVAR (1) | N/P | 45 (16, 60) |

(Continued)
dissection was classified as acute in 98% (146/149) of cases, acute-on-chronic in 0.7% (1/149) of cases, and chronic in 1.3% (2/149) of cases.

Clinical presentation was reported in 91.8% (34/37) of studies. Presentation and symptoms are reported in Table 1. The most common symptom in patients with MesMP was abdominal pain. Other concomitant clinical and radiographic malperfusion are reported in Table 1. MesMP was the sole ischemic complication in 26% (38/149) of patients and was accompanied by renal malperfusion alone in 22.1% (33/149) of patients, lower-extremity malperfusion alone in 15.4% (23/149), and both renal and lower-extremity malperfusion in 36.9% (55/149).

**Treatment**

Surgical and endovascular treatments were performed in 35 of 149 (23.5%) and 112 of 149 (75.2%) patients, respectively, whereas 2 patients (1.3%) had combination procedures. In the surgical group, open aortic reconstruction (open fenestration, open stenting, or open aortic replacement with graft), direct anatomic bypass, or indirect anatomic bypass were performed in 29 of 35 (82.8%), 4 of 36 (11.4%), and 2 of 35 (5.7%) cases, respectively. In the endovascular group, a thoracic endograft or an aortic stent alone was placed in 22 of 112 (19.6%) of cases, percutaneous fenestration alone was performed in 5/112 (4.5%) of cases, and branch stenting alone was performed in 17 of 112 (15.2%) of cases. A combination of TEVAR or aortic stent + fenestration, TEVAR or aortic stent + branch stenting, or fenestration + branch stenting was performed in 22 of 112 (19.6%), 5 of 112 (4.5%), 41 of 112 (36.6%), and of cases, respectively. Overall, 43.7% (49/112) of patients had only aortic interventions, whereas 56.3% (63/112) required a branch vessel intervention. Two patients had combination procedures, including one patient who had aortic fenestration then 6 hours later an SMA stent placed immediately followed by open direct anatomic bypass \((n = 1)\) and 1 patient an open ascending/arch replacement with frozen elephant trunk and branch vessel stenting \((n = 1)\). Preoperative demographics, including age, sex, and dissection type, were similar between the endovascular and open repair groups. Concomitant renal, lower extremity, or renal + lower-extremity malperfusion was also similar between these 2 groups (Table 3).

**Procedural/Surgical Outcomes**

Overall in-hospital mortality was 12.8% (19/149). A summary of procedural and clinical outcomes is provided in Table 2. Clinical success, defined as resolution of malperfusion without in-hospital mortality, was similar between surgical and endovascular approaches (86.1% vs 84.4%) as was in-hospital mortality (11.4% vs 13.4%, \(P = .762\)). Necessity for bowel resection was also similar between surgical and endovascular approaches (14.3% vs 9.8%, respectively).
TABLE 3. Demographics, procedures, and outcomes among the open and endovascular repair treatment strategies for TBAD and MesMP

|                      | Total (n = 149) | Open repair (n = 35) | Endovascular repair (n = 112) | P value |
|----------------------|----------------|---------------------|-----------------------------|---------|
| **Demographics**     |                |                     |                             |         |
| Age                  | 55 (46, 65)    | 57 (48, 68)         | 53.5 (46, 63)               | .103    |
| Sex, male            | 117 (79)       | 28 (80)             | 88 (79)                     | .532    |
| **Dissection type**  |                |                     |                             |         |
| Acute                | 146 (98)       | 35 (100)            | 109 (97)                    | .439    |
| Acute-on-chronic     | 1 (0.7)        | 0 (0)               | 1 (0.9)                     |         |
| Chronic              | 2 (1.3)        | 0 (0)               | 2 (1.8)                     |         |
| **Additional malperfusion** |        |                     |                             |         |
| Renal                | 33 (22)        | 5 (14)              | 26 (23)                     | .074    |
| Lower extremity      | 23 (15)        | 9 (26)              | 14 (12.5)                   |         |
| Renal + lower extremity | 55 (37)   | 9 (26)              | 46 (41)                     |         |
| **Procedure**        |                |                     |                             |         |
| Aortic fenestration  | 87 (58)        | 16 (46)             | 70 (62.5)                   | .059    |
| Aortic stenting      | 40 (27)        | 10 (29)             | 29 (26)                     | .455    |
| Branch vessel stenting* | 48 (32) | 1 (2.9)             | 45 (40)                     | <.005   |
| Open aortic replacement | 9 (6.0) | 7 (20)              | 0 (0)                       | <.005   |
| Open bypass*         | 5 (3.4)        | 4 (11)              | 0 (0)                       | .003    |
| **Outcomes**         |                |                     |                             |         |
| Bowel resection      | 17 (11)        | 5 (14)              | 11 (9.8)                    | .267    |
| In-hospital mortality| 19 (13)        | 4 (11)              | 15 (13)                     | .509    |

Data presented as median (25%, 75%) for continuous data and n (%) for categorical data. TBAD, Type B aortic dissection; MesMP, mesenteric malperfusion. *Branch vessel stenting and open bypass for the treatment of mesenteric malperfusion, stenting and bypass for other vascular territories not included.

P = .459 (Table 3). Within the surgical approach group (n = 35), systemic complications included multiorgan failure (n = 3), and acute renal failure (n = 2). Within the endovascular approach group (n = 112), systemic complications included conversion to type A dissection during TEVAR (n = 2), intraoperative aortic injury from sheath during

TABLE 4. Demographics, procedures, and outcomes among surgical strategies for TBAD and MesMP

|                      | Total (n = 35) | Open aortic replacement (n = 7) | Open fenestration or stenting (n = 21) | Vascular bypass or other* (n = 7) |
|----------------------|----------------|-------------------------------|---------------------------------------|----------------------------------|
| **Demographics**     |                |                               |                                       |                                  |
| Age                  | 57 (48, 68)    | 57 (40, 63)                   | 56 (47, 65)                           | 68 (61, 77)                      |
| Sex, male            | 28 (80)        | 6 (86)                        | 16 (76)                               | 6 (86)                           |
| **Dissection type**  |                |                               |                                       |                                  |
| Acute                | 35 (100)       | 7 (100)                       | 21 (100)                              | 7 (100)                          |
| Acute-on-chronic     | 0 (0)          | 0 (0)                         | 0 (0)                                 | 0 (0)                            |
| Chronic              | 0 (0)          | 0 (0)                         | 0 (0)                                 | 0 (0)                            |
| **Additional malperfusion** |       |                               |                                       |                                  |
| Renal                | 5 (14)         | 2 (29)                        | 3 (14)                                | 0 (0)                            |
| Lower extremity      | 9 (26)         | 1 (14)                        | 6 (29)                                | 2 (29)                           |
| Renal + lower extremity | 9 (26)   | 2 (29)                        | 5 (24)                                | 2 (29)                           |
| **Procedure**        |                |                               |                                       |                                  |
| Aortic fenestration  | 16 (46)        | 2 (29)                        | 13 (62)                               | 0 (0)                            |
| Aortic stenting      | 10 (29)        | 2 (29)                        | 8 (38)                                | 0 (0)                            |
| Branch vessel stenting* | 1 (2.9)  | 1 (14)                        | 0 (0)                                 | 0 (0)                            |
| Open aortic replacement | 7 (20)  | 7 (100)                       | 0 (0)                                 | 0 (0)                            |
| Open bypass*         | 4 (11)         | 0 (0)                         | 0 (0)                                 | 4 (57)                           |
| **Outcomes**         |                |                               |                                       |                                  |
| Bowel resection      | 5 (14)         | 3 (43)                        | 0 (0)                                 | 2 (29)                           |
| In-hospital mortality| 4 (11)         | 1 (14)                        | 3 (14)                                | 0 (0)                            |

Data presented as median (25%, 75%) for continuous data and n (%) for categorical data. TBAD, Type B aortic dissection; MesMP, mesenteric malperfusion. *Other includes branch vessel thrombectomy, branch vessel fenestration, and branch vessel patch repair. [Branch vessel stenting and open bypass for the treatment of mesenteric malperfusion, stenting and bypass for other vascular territories not included.]
TEVAR (n = 1), multiorgan failure (n = 2), respiratory failure (n = 2), acute renal failure (n = 1), and subacute ischemic infarcts with right-sided weakness (n = 1). Among the 2 patients receiving combination procedures, 50% (1/2) required a bowel resection and in-hospital mortality was 0%.

Within the surgical approaches, bowel resection was performed in 42.9% (3/7) of patients undergoing open aortic replacement, 0% (0/21) of patients undergoing open aortic fenestration or stenting, and 28.6% (2/7) of patients undergoing open bypass or other open procedure. In-hospital mortality was 14.3% in the open aortic replacement group, 14.3% in the open aortic fenestration or stenting group, and 0% in the open bypass or other open procedure group (Table 4). Statistical testing evaluating significance of difference between these subgroups was not performed given the small sample size and bias associated with multiple testing. Within the endovascular approaches, necessity for bowel resection was similar between any TEVAR and fenestration/stenting without TEVAR groups.

### Table 5. Demographics, procedures, and outcomes among open endovascular strategies for TBAD and MesMP

| Demographics | Total (n = 112) | Any TEVAR (n = 21) | Fenestration/stenting w/o TEVAR (n = 91) | P value |
|--------------|---------------|-------------------|----------------------------------------|--------|
| Age          | 53.5 (46, 63) | 60 (46, 69)       | 53 (46, 61)                            | 405    |
| Sex, male    | 88 (79)       | 11 (55)           | 77 (85)                                | <.005  |
| Dissection type |          |                  |                                        | .215   |
| Acute        | 109 (97)      | 20 (95)           | 89 (98)                                |        |
| Acute-on-chronic | 1 (0.9)    | 1 (4.8)           | 0 (0)                                  |        |
| Chronic      | 2 (1.8)       | 0 (0)             | 2 (2.2)                                |        |
| Additional malperfusion |       |                  |                                        | .558   |
| Renal        | 26 (23)       | 4 (19)            | 22 (24)                                |        |
| Lower extremity | 14 (12.5) | 4 (19)            | 10 (11)                                |        |
| Renal + lower extremity | 46 (41) | 5 (24)            | 41 (45)                                |        |
| Procedure |            |                  |                                        |        |
| Aortic fenestration | 70 (62.5) | 0 (0)             | 70 (77)                                | <.005  |
| Aortic stenting | 29 (26)   | 2 (9.5)           | 27 (30)                                | .944   |
| Branch vessel stenting* | 45 (40) | 2 (9.5)           | 43 (47)                                | <.005  |
| Outcomes |            |                  |                                        |        |
| Bowel resection | 11 (9.8)  | 2 (9.5)           | 9 (9.9)                                | .999   |
| In-hospital mortality | 15 (13)  | 5 (24)            | 10 (11)                                | .153   |

Data presented as median (25%, 75%) for continuous data and n (%) for categorical data. TEVAR, Thoracic endovascular aortic repair; TBAD, type B aortic dissection; MesMP, mesenteric malperfusion. *Branch vessel stenting for the treatment of mesenteric malperfusion, stenting and bypass for other vascular territories not included.

### Table 6. Logistic regression of study author and intervention on in-hospital mortality

| Intervention | Coefficient | Standard error | Wald test | P value |
|--------------|-------------|----------------|-----------|---------|
| Endovascular |             |                |           |         |
| Surgical     | 1.121       | 1.154          | 0.944     | .331    |
| Study        | 5.815       |                | 1.000     | .999    |

| Author       | Coefficient | Standard error | Wald test | P value |
|--------------|-------------|----------------|-----------|---------|
| Verhoye et al, 2008 | 1.121       | 1.154          | 0.944     | .331    |
| Slonim et al, 1996 | 19.060       | 28,421.33      | 0.000     | .999    |
| Styroeras et al, 2011 | 18.120       | 28,421.33      | 0.000     | .999    |
| Trimarchi et al, 2010 | 20.642       | 28,421.33      | 0.000     | .999    |
| Panneton et al, 2000 | 19.676       | 28,421.33      | 0.000     | .999    |
| Lauterbach et al, 2001 | -1.121      | 33,628.37      | 1.000     | .999    |
| Uchida et al, 2009 | 20.104       | 28,421.33      | 0.000     | .999    |
| Vedantham et al, 2003 | 19.533       | 28,421.33      | 0.000     | .999    |
| Norton et al, 2020 | -1.121       | 34,808.63      | 0.000     | 1.000   |
| Axtell et al, 2020 | 19.388       | 28,421.33      | 0.000     | .999    |
The management of aortic disease has seen an evolution particularly through 2007 and 81% of cases treated endovascularly in 75% of TBADs with MesMP were managed endovascularly in 75% of cases, surgically in 23%, and with open + endovascular combination in 2% of cases (Figure 2). Bowel resection was performed in 11% of patients, and overall in-hospital mortality was 12.8% and was similar between endovascular and surgical strategies (13% vs 11%). This study underscores the severity of TBAD with MesMP as well as many different management strategies. A summary of the findings, as well as an example case of endovascular management of TBAD + MesMP is presented in the Video Abstract.

The management of aortic disease has seen an evolution in treatment strategy with the advent of new technologies, in particular endovascular therapies such as stent grafting. The increased use of endovascular therapies as seen in International Registry of Acute Aortic Dissection (IRAD) was evident in this review, with 71% of cases treated endovascularly through 2007 and 81% of cases after 2007. However, over the past 13 years, ~20% of TBADs with MesMP were managed with an open surgical strategy or combination endovascular and open strategy. Due to the many treatment strategies available, multiple aspects need to be considered when deciding the optimal strategy for each patient. First, one must consider the capabilities of both institution and physician as well as the working relationship between specialties of interventional radiology, cardiothoracic surgery, vascular surgery, and general surgery. The facility and physician must be comfortable with the chosen strategy. The highly variable strategies presented in this review highlight the differences in practice patterns, with each noncase report manuscript predominantly presenting one treatment option. For example, the studies by Verhoye and colleagues and Sfyroeras and colleagues present TEVAR, the study by Trimarchi and colleagues presents a hybrid approach with open total arch replacement and frozen elephant trunk placement, and the study by Norton and colleagues presents endovascular fenestration/stenting. Second, the specific patient must be considered, including age, sex, comorbidities, dissection characteristics and extent, vascular territories malperfused, and type of malperfusion.

As pioneered by Williams and colleagues, obstruction caused by aortic dissection can be static, dynamic, or a combination of the two, with the different etiologies determining treatment strategy. Dynamic obstruction results from the dissection flap of a collapsed true lumen prolapsing across the orifice of a branch vessel, such as the SMA, prohibiting flow into the branch vessel. Dynamic obstruction can be intermittent and vary in severity depending on the blood pressure. Static obstruction results from extension of dissection into a branch vessel without adequate re-entry, often causing false lumen thrombosis in the branch artery. While dynamic obstruction can be treated with open aortic repair or TEVAR with covering of the intimal tear, static obstruction usually requires targeted branch vessel obstructions.
intervention such as branch vessel stenting, thrombolysis, or thromboembolectomy. Therefore, the first step in managing TBAD with suspected MesMP (which presumes the physicians have some imaging confirmation of the dissection and some appreciation of the ongoing mechanism of possible obstruction) should be blood pressure control to limit severity of dynamic obstruction. In this review, 32% of patients required branch vessel stenting, and 3% had a direct vascular bypass, suggesting the presence of static obstruction. However, this is much lower than that reported in patients with TBAD and visceral malperfusion in an IRAD study,\(^6\) in which ~80% had evidence on CT scan of branch vessel involvement. Among those undergoing endovascular management, branch vessel stenting was much more prevalent in the fenestration/stenting group compared to the TEVAR group (47% vs 9.5%, \(P < .005\)). Therefore, in patients in which static obstruction is suspected (ie, those with branch vessel involvement on CT), endovascular fenestration/stenting could be the preferred strategy so that both dynamic and static obstruction can be addressed at the time of intervention.

With each patient in mind, risks of each procedure should be considered. For an open strategy, can a patient tolerate that open procedure? The strategy of open arch replacement with frozen elephant trunk requires cardiopulmonary bypass and crossclamping of the aorta. TEVAR requires an adequate landing zone and has associated risks, including retrograde type A dissection (n = 2 in this survey), risk of paralysis (not captured in this review) due to false lumen or intercostal artery thrombosis (not reported with fenestration/stenting\(^6\)), and determining if it can resolve the malperfusion, especially if there is static obstruction, and risk of graft infection, especially in the presence of dead bowel. Fenestration/stenting allows quick assessment of hemodynamics and enables each branch vessel to be investigated,\(^50\) but it requires expertise from interventional radiology and is not available at all hospitals. Complications of infradiaphragmatic arterial obstruction in this study, including renal failure and multisystem organ failure, were present in patients treated by both surgical and endovascular strategies. Two patients (1.8%) who underwent endovascular management, both TEVAR, suffered conversion to type A dissection. Each intervention and associated risks need to be considered for each specific individual patient, and the selected strategy should be tailored to the patient. In addition, the available physician and treatment team partially determines the choice of treatment. For example, if a cardiac surgeon is managing the patient, TEVAR is a valid option, but if an interventional radiologist is on the aortic team, then endovascular fenestration/stenting is also an option. Ideally, all of the treatment strategies are tools in the toolbox in the management of TBAD with MesMP, and the optimal treatment strategy will vary by facility, physician, and patient.\(^50\) Hospitals can consider incorporating a MesMP response team to get all experts on board and decide on a patient-specific treatment, as numerous hospitals have done for the management of pulmonary embolism.\(^51,52\)

Following visceral reperfusion, a surgical consult should be placed to determine whether diagnostic laparoscopy/exploratory laparotomy is required, as it has been shown to decrease mortality.\(^6,53\) Discriminating between adequate and inadequate mesenteric perfusion by visual and manual inspection of the bowel is more reliable after endovascular relief of obstruction of the SMA. In some circumstances, local surgical and endovascular facilities can enable bowel inspection at the time of reperfusion, as seen in included reports.\(^33,34,37,39,41,47\) In total, 17% (25/149) underwent diagnostic laparoscopy/exploratory laparotomy and bowel inspection, and 11% (17/149) underwent bowel resection, with similar rates of bowel resection among endovascular and open surgical strategies (10% vs 14%).

The overall in-hospital mortality of 13% for MesMP in this review is likely underestimated secondary to publication bias, since any visceral ischemia in the setting of TBAD is associated with a mortality of 31% per IRAD data.\(^49\) Variable institutional definitions of malperfusion may also affect IHM. Endovascular and surgical management groups had similar mortality (11% vs 13%) in this cohort of TBAD with MesMPS, underscoring the severity of MesMPS in the setting of TBAD. In addition, malperfusion of additional vascular territories is associated with an increase in mortality.\(^54\)

This study is limited by available data and reported outcomes in manuscripts; therefore, more specific complication rates and hospital lengths of stay were unable to be determined. This study is also limited by sample size with a possibility of type II error. There are currently no standard guidelines for reporting of clinical outcome measures or mortality data, and thus a more general definition of inhospital mortality was used as described above and no time-dependent patient outcomes, such as 30-day mortality, were analyzed. We hope this study serves as an impetus for future studies to present this data. In addition, the anatomical spectrum of SMA obstruction is not reported in most reviews, which limits comparison of mechanisms. There are currently no large prospective data sets comparing combinations of endovascular modalities, especially in the treatment of complicated TBAD. Future studies that compare these modalities, specifically looking at static versus dynamic malperfusion, are warranted.

**CONCLUSIONS**

Type B aortic dissection complicated with MesMP is a serious condition with open, endovascular, and hybrid treatment strategies available. Necessity for bowel resection and in-hospital mortality was similar between open and
endovascular strategies; however, endovascular management is the most commonly used strategy.

Conflict of Interest Statement
M.S.K. reported speaking honoraria from Penumbra, Inc, Boston Scientific, and Medtronic; and grant funding from Boston Scientific, Inc, and the SIR Foundation, none of which are relevant to this paper. D.M.W. reported Medical Advisory Board of Boston Scientific, which is not relevant to this paper. All other authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

References
1. Tadros RO, Tang GHL, Barnes HJ, Mousavi I, Kovacic JC, Fairies P, et al. Optimal treatment of uncomplicated type B aortic dissection: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74:1494-504.
2. Fattori R, Tsai TT, Mymryl T, Evangelista A, Cooper JV, Trimarchi S, et al. Complicated acute type B dissection: is surgery still the best option? A report from the International Registry of Acute Aortic Dissection. JACC Cardiovasc Interv. 2008;1:395-402.
3. Velayudhan BV, Idhrees AM, Mukesh K, Kannan RN. Mesenteric malperfusion in acute aortic dissection: challenges and frontiers. Semin Thorac Cardiovasc Surg. 2019;31:668-73.
4. Yang B, Norton EL, Rosati CM, Wu X, Kim KM, Khaja MS, et al. Managing patients with acute type A aortic dissection and mesenteric malperfusion syndrome: 20-year experience. J Thorac Cardiovasc Surg. 2019;158:675-87.
5. Williams DM, Brothers TE, Messina LM. Relief of mesenteric ischemia in type III aortic dissection with percutaneous fenestration of the aortic septum. Radiology. 1990;197:450-2.
6. Norton EL, Williams DM, Kim KM, Khaja MS, Wu X, Patel HJ, et al. Management of acute type B aortic dissection with malperfusion via endovascular fenestration/stenting. J Thorac Cardiovasc Surg. 2020;160:1151-61.e1.
7. Hughes GC, Andersen ND, McCann RL. Management of acute type B aortic dissection. J Thorac Cardiovasc Surg. 2013;145:S202-7.
8. Wilkinson DA, Patel HJ, Williams DM, Dasika NL, Deeb GM. Early open and endovascular thoracic aortic repair for complicated type B aortic dissection. Ann Thorac Surg. 2013;96:23-30; discussion 230.
9. Eggebrecht H, Nienaber CA, Neuhauser M, Baumgart D, Kische S, Schmermund A, et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. Eur Heart J. 2006;27:489-98.
10. Szeto WY, McGarvey M, Pochettino A, Moser GW, Hoboken A, Cornelius K, et al. Results of a new surgical paradigm: endovascular repair for acute complicated type B aortic dissection. N Engl J Med. 1999;340:1359-45.
11. Zeeshan A, Woo EY, Bavaria JE, Fairman RM, Desai ND, Pochettino A, et al. Thoracic endovascular aortic repair for acute complicated type B aortic dissection: superiority relative to conventional open surgical and medical therapy. J Thorac Cardiovasc Surg. 2010;140:S109-15; discussion S142-6.
12. Shanser L, Moher D, Clarke M, Gheri D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g6747.
13. Shiba N, Matsuoka K, Kunitahara T, Murashita T, Matsui Y. Management of vital organ malperfusion in acute aortic dissection: proposal of a mechanism-specific approach. Gen Thorac Cardiovasc Surg. 2007;55:85-90. https://doi.org/10.1007/s11748-006-0080-4.
14. Miyachi H, Omowara S, Akutsu K, Shimizu W, Kunita SI, Tanaka K, et al. Treatment of visceral malperfusion in acute type B aortic dissection by percutaneous endovascular fenestration using a stent, with additional stenting of the true lumen. J Nippon Med Sch. 2014;81:340-5.
15. Suzuki K, Shimohira M, Hashizume T, Shibamoto Y. Sient placement for acute superior mesenteric artery occlusion associated with type B aortic dissection. Circ J. 2015;79:1845-141.
16. Yamakado K, Takeda K, Nomura Y, Kato N, Hirano T, Matsumura K, et al. Relief of mesenteric ischemia by Z-stent placement into the superior mesenteric artery compressed by the false lumen of an aortic dissection. Cardiovasc Intervent Radiol. 1998;21:66-8.
17. Yoshida R, Morisaki K, Matsubara Y, Yoshiya K, Inoue K, Matsuda D, et al. Emergency thoracic aortic stent grafting for acute complicated type B aortic dissection after a previous abdominal endovascular aneurysm repair. Surg Case Rep. 2015;1:99.
18. Kazemi Z, Ryno P, Gutowski P, Jedrzejczak T. Endovascular stenting of a complicated type B aortic dissection in an 11-year-old patient: case report. Medicine (Baltimore). 2018;57:e0279.
19. Leprince P, Cluzel P, Bonnet N, Iztillo R, Pavie A, Gandjbakhch I. An endovascular stent relieves celiac and mesenteric ischemia in acute aortic dissection. Ann Thorac Surg. 2004;78:e3-5.
20. Ito N, Tsunoda M, Nakamura M, Iijima R, Matsuda K, Suzuki T, et al. Percutaneous bare Z-stent implantation as an alternative to surgery for acute aortic dissection with visceral ischemia. Catheter Cardiovasc Interv. 2003;58:95-100.
21. Bao Q, Chen L. Thrombotic mesenteric ischemia due to aortic dissection. J Vasc Interv Radiol. 2010;52:167a.
22. Chang WT, Kao HL, Liao CS, Lee YT. Aortic stenting on a type B aortic dissection with visceral ischemia. Catheter Cardiovasc Interv. 2001;52:112-5.
23. Payabayb EC, Maloney AH, Brinster DR. Understent stents for acute mesenteric ischemia in chronic type B dissection. Ann Thorac Surg. 2017;103:e501-3.
24. Petrelli G, Puppini G, Calzaferri D, Torre S, Bagana A, Faggian G. Emergency thoracic endovascular aneurysm repair in acute type B dissection with visceral malperfusion. Aorta (Stamford). 2013;1:206-9.
25. Santo K, McCafferty I, Guest P, Bomser R. A fatal complication following hybrid total arch replacement with supra-aortic artery translocation and endovascular stenting. Eur J Vasc Endovasc Surg. 2007;34:534-6.
26. Son SA, Lee YO, Kim GI, Cho JY, Lee JT. Placement of endovascular stent graft in acute malperfusion syndrome after acute type II aortic dissection. Korean Cir J. 2012;42:638-40.
27. Iyer V, Rigby M, Vrabec G, Sr. Type B aortic dissection after endovascular abdominal aortic aneurysm repair causing endograft collapse and severe malperfusion. J Vasc Surg. 2009;50:413-6.
28. Verhooyt JP, Miller DC, Sere D, Duke MD, Mitchell RS. Complicated acute type B aortic dissection: midterm results of emergency endovascular stent-grafting. J Thorac Cardiovasc Surg. 2008;136:424-30.
29. Slimon SM, Nyman U, Semba CP, Miller DC, Mitchell RS, Duke MD. Aortic dissection: percutaneous management of ischemic complications with endovascular stents and balloon fenestration. J Vasc Surg. 1996;23:241-51; discussion 251-3.
30. Sfryroeras GS, Rubio V, Pagan P, Dietrich EB, Rodriguez JA. Endovascular management of malperfusion in acute type B aortic dissections. J Endovasc Ther. 2011;18:78-86.
31. Imai CH, Chang KH, Chang SL, Lai HC, Lee WL, Liu TJ. Rescue intervention after three days of renal ischemia caused by acute complicated type B aortic dissection. Perfusion. 2018;33:156-9.
32. Filippine G, Ferro G, Duranti C, La Barbera G, Talarico F. Simultaneous surgical treatment of type B dissection complicated with visceral malperfusion and abdominal aortic aneurysm: role of aortic fenestration. Aorta (Stamford). 2013;1:126-30.
33. Howel IF, LeMaure SA, Kirby RP. Thoracoabdominalfenestration for aortic dissection with ischemic colonic perforation. Ann Thorac Surg. 1997;64:242-4.
34. Kalangos A, Gemayel G, Vala D, Khabiri E, Mugnai D, Murith N. Ascending aorto-superior mesenteric artery bypass as a surgical option for revascularization in mesenteric ischemia associated with type B aortic dissection. Ann Thorac Surg. 2014;28(1036.e1-3.
35. Kao EH, Lai HC, Chang YW, Wang CC, Lee WL, Chan SW, et al. Axillofemoral bypass relieves visceral malperfusion in type B aortic dissection. Ann Thorac Surg. 2013;95:703-5.
36. Kurumisawa S, Sugaya A, Akutsu H, Takazawa I, Ohki SI, Misawa Y. Delayed visceral ischemia induced by type B aortic dissection. Acute Med Surg. 2015;2:131-3.
37. Okada K, Sueda T, Orihashi K, Imai K, Sugawara Y, Hamamoto M. Rescue visceral revascularization without direct aortic surgery to treat malperfusion complicating type B aortic dissection. Ann Thorac Surg. 2005;80:818-20.
38. Saiota Y, Ohmori H, Hari Y, Setozaki S, Harada H, Sueda T. Mesenteric artery fenestration for type B dissection with visceral ischemia. Asian Cardiovasc Thorac Ann. 2012;20:465-5.
40. Wang N, Wong DT, Rivera JL, Bansal RC, Gundry SR. Repair of acute descending aortic dissection complicated by visceral ischemia. Ann Thorac Surg. 1999; 68:1067-8; discussion 1068-9.

41. Yamashiro S, Kuniyoshi Y, Miyagi K, Uezu T, Arakaki K, Koja K. Type B dissection complicated by subacute visceral ischemia. Asian Cardiovasc Thorac Ann. 2004;12:162-4.

42. Kim KH, Choi JB, Kuh JH. Simultaneous relief of acute visceral and limb ischemia in complicated type B aortic dissection by axilllobifemoral bypass. J Thorac Cardiovasc Surg. 2014;147:524-5.

43. Trimarchi S, Jonker FH, Muhs BE, Grassi V, Righini P, Upchurch GR, et al. Long-term outcomes of surgical aortic fenestration for complicated acute type B aortic dissections. J Vasc Surg. 2010;52:261-6.

44. Axtell A, Eagleton M, Conrad M, Isselbacher E, Sundt T, Jassar A. Total arch replacement and frozen elephant trunk for acute complicated type B dissection. Ann Thorac Surg. 2020;110:e213-6.

45. Panneton JM, Teh SH, Cherry KJ Jr, Hofer JM, Gloviczki P, Andrews JC, et al. Aortic fenestration for acute or chronic aortic dissection: an uncommon but effective procedure. J Vasc Surg. 2000;32:711-21.

46. Lauterbach SR, Cambria RP, Brewster DC, Gertler JP, Lamuraglia GM, Isselbacher EM, et al. Contemporary management of aortic branch compromise resulting from acute aortic dissection. J Vasc Surg. 2001;33:1185-92.

47. Uchida N, Shibamura H, Katayama A, Aishin K, Sutoh M, Kuraoka M. Surgical strategies for organ malperusions in acute type B aortic dissection. Interact Cardiovasc Thorac Surg. 2009;8:75-8.

48. Vedantham S, Picus D, Sanchez LA, Braverman A, Moon MR, Sundt T 3rd, et al. Percutaneous management of ischemic complications in patients with type-B aortic dissection. J Vasc Interv Radiol. 2003;14:181-94.

49. Jonker FH, Patel HJ, Upchurch GR, Williams DM, Montgomery DG, Gleason TG, et al. Acute type B aortic dissection complicated by visceral ischemia. J Thorac Cardiovasc Surg. 2015;149:1081-6.e1.

50. Yang B, Williams D. Reply from Authors: thoracic endovascular aortic repair versus fenestration/stenting: both effective weapons for the same disease. J Thorac Cardiovasc Surg. 2021;161:e368-9.

51. Wright C, Goldenberg L, Schleede S, McNitt S, Gosev I, Elbadawi A, et al. Effect of a multidisciplinary pulmonary embolism response team on patient mortality. Am J Cardiol. 2021;161:102-7.

52. Myc LA, Solanki JN, Barros AJ, Nuradin N, Nevulis MG, Earasi K, et al. Adoption of a dedicated multidisciplinary team is associated with improved survival in acute pulmonary embolism. Respir Res. 2020;21:159.

53. Elharawy JG, Elman YM, Zenati M, Simmons RL, Rosengart MR. Acute mesenteric ischemia: the importance of early surgical consultation. Am Surg. 2009;75:212-9.

54. Girdauskas E, Kuntze T, Borger MA, Falk V, Mohr FW. Surgical risk of preoperative malperfusion in acute type A aortic dissection. J Thorac Cardiovasc Surg. 2009;138:1363-9.

Key Words: type B aortic dissection, mesenteric malperfusion, visceral malperfusion, fenestration, aortic stenting, thoracic endovascular aortic repair